Class III β-tubulin, but not ERCC1, is a strong predictive and prognostic marker in locally advanced head and neck squamous cell carcinoma

Abstract

TUBB3 is a predictive and prognostic marker along with well-known p53 in HNSCC patients receiving cisplatin-based induction chemotherapy. Clinical impact of ERCC1 is not evident in this setting.

Expression of Class III Beta-tubulin Predicts Prognosis in Patients with Cisplatin-resistant Bladder Cancer Receiving Paclitaxel-based Second-line Chemotherapy

“…Therefore, prediction of the anticancer effects of cisplatin-based chemotherapy is important in planning treatment strategies. In several malignancies, increased expression of TUBB3 was reported to be significantly associated with poor prognosis and survival in patients receiving platinum-based chemotherapy (24,25). Therefore, we expected that TUBB3 expression would be significantly associated with the anticancer effect of cisplatin-based chemotherapy in patients with advanced UC; however, our results did not support this hypothesis.…”

ERCC1 protein, mRNA expression and T19007C polymorphism as prognostic markers in head and neck squamous cell carcinoma patients treated with surgery and adjuvant cisplatin-based chemoradiation

“…A similar deleterious effect for high ERCC1 expression was shown in 45 HNSCC patients treated with cisplatin-based chemoradiation (25), and also among 34 HNSCC treated by induction chemotherapy (cisplatin and docetaxel) followed by concurrent cisplatinbased chemoradiation (26). More recently, two other studies have shown no influence on response rate or survival for ERCC1 expression in HNSSC patients treated by cisplatinbased induction chemotherapy, followed by radiation therapy or radical surgery, or concurrent cisplatin, radiotherapy and cetuximab (27,28). On the other hand, studies done in two other tobacco-related cancers, namely non-small cell lung cancer and pancreatic adenocarcinoma, treated by surgery alone, indicate that ERCC1 positivity may implicate in a favorable prognosis, which is in line with our results (13,14,29).…”

The miR-200 family controls -tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients

“…Interestingly, we found classes II and III b-tubulin Endocrine-Related Cancer (2011) 18 85-95 www.endocrinology-journals.org expression to be mutually exclusive, suggesting a complex regulatory mechanism. In other tumor types, isotype III has been detected in 36% of gastric (Urano et al 2006), 40% of head and neck (Koh et al 2009), and 84% of breast (Paradiso et al 2005) cancer samples respectively. b-tubulin III tumoral overexpression has been associated with poor prognosis in a variety of cancer types (Seve et al 2005, Seve & Dumontet 2008, Koh et al 2009, including ovarian carcinomas (Ferrandina et al 2006), although there is one contradictory report (Aoki et al 2009) in clear cell ovarian cancer patients.…”

“…In ovarian carcinoma, high protein levels of classes I and IV, intermediate levels of class III, and low levels of class II b-tubulin have been reported (Ohishi et al 2007). High tumoral b-tubulin III expression has been associated with worse survival in non-small cell lung cancer (Rosell et al 2003, Seve et al 2005, breast (Seve & Dumontet 2008), head and neck (Koh et al 2009), and ovarian cancer (Ferrandina et al 2006), although Aoki et al (2009) reported a better survival for patients with ovarian clear cell adenocarcinoma positive for class III expression. In ovarian cancer, b-tubulin III has also been associated with worse treatment response (Kavallaris et al 1997, Mozzetti et al 2005, Umezu et al 2008.…”